Karuna Therapeutics

Youtube Subscribe

Open: 222.0 Close: 226.55 Change: 4.55

The best way to get informed about Karuna Therapeutics Stock without reading hundreds of pages.

The game is changing. There is a new strategy to evaluate Karuna Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Karuna Therapeutics are: Karuna, Therapeutics, year, KRTX, last, biopharmaceutical, company, …

Concept Map

Semantic Network

Stock Summary

Karuna Therapeutics, Inc. creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for.

Today's Summary

Karuna Therapeutics (KRTX) investors will be pleased with their splendid 165% return over the last three years. Investing in Karuna three years ago would have delivered you a 144% gain. CFO Troy A. Ignelzi sold 9,000 shares of Karuna stock in a transaction dated Tuesday, May 23rd.

Today's News

Karuna Therapeutics (KRTX) investors will be pleased with their splendid 165% return over the last three years. Investing in Karuna three years ago would have delivered you a 144% gain. The clinical-stage biopharmaceutical company, which focuses on therapies affecting the central nervous system. Zacks Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates KarunaTherapeutics is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. Karuna Therapeutics (NASDAQ:KRTX) opened trading at $220.17 on Monday, with a fifty-day moving average of $198.96 and a two-hundred-day moving average of $200.91. Forbes estimates indicate that Karuna Therapeutics market capitalization increased by 352.5% from $1.82 billion last year. Karuna Therapeutics to Present at Upcoming Investor Conferences. CFO Troy A. Ignelzi sold 9,000 shares of Karuna. stock in a transaction dated Tuesday, May 23rd.

Stock Profile

"Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Karuna Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Karuna Therapeutics are: Karuna, Therapeutics, year, KRTX, last, biopharmaceutical, company, and the most common words in the summary are: therapeutic, karuna, inc, view, analyze, report, schizophrenia, . One of the sentences in the summary was: CFO Troy A. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #karuna #inc #view #analyze #report #schizophrenia.

Read more →

Youtube Subscribe

---